Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  845 results for ""Deoxycytidine""

Your Filters

Subject : carcinoma, pancreatic ductal
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Epigenetic Activation of the CMTM6-IGF2BP1-EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.

  • Authors : Zhu YQ; Department of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.; Huang Y

Subjects: Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/pharmacology ; Gemcitabine*

  • Source: Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2024 Dec; Vol. 11 (47), pp. e2406714. Date of Electronic Publication: 2024 Nov 03.Publisher: WILEY-VCH Country of Publication: Germany NLM ID: 101664569 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2198-3844

Record details

Read More Add to Saved list
×
Academic Journal

Nrf2-mediated adenylosuccinate lyase promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma cells through ferroptosis escape.

  • Authors : Hsu TW; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.; Department of Surgery, Division of General Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.

Subjects: Gemcitabine* ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/pharmacology

  • Source: Journal of cellular physiology [J Cell Physiol] 2024 Dec; Vol. 239 (12), pp. e31416. Date of Electronic Publication: 2024 Aug 20.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0050222 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer.

  • Authors : Wei D; State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China.; Yuan L

Subjects: Gemcitabine* ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/pharmacology

  • Source: Cancer letters [Cancer Lett] 2024 Nov 28; Vol. 605, pp. 217284. Date of Electronic Publication: 2024 Oct 02.Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial.

  • Authors : Cheng K; Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.; Li X

Subjects: Carcinoma, Pancreatic Ductal*/Carcinoma, Pancreatic Ductal*/Carcinoma, Pancreatic Ductal*/drug therapy ; Carcinoma, Pancreatic Ductal*/Carcinoma, Pancreatic Ductal*/Carcinoma, Pancreatic Ductal*/immunology ; Carcinoma, Pancreatic Ductal*/Carcinoma, Pancreatic Ductal*/Carcinoma, Pancreatic Ductal*/pathology

  • Source: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Nov 25; Vol. 9 (1), pp. 321. Date of Electronic Publication: 2024 Nov 25.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Tumor-Colonizing E. coli Expressing Both Collagenase and Hyaluronidase Enhances Therapeutic Efficacy of Gemcitabine in Pancreatic Cancer Models.

  • Authors : Avsharian LC; Department of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.; Irell and Manella Graduate School of Biological Sciences, City of Hope, Duarte, CA 91010, USA.

Subjects: Hyaluronoglucosaminidase*/Hyaluronoglucosaminidase*/Hyaluronoglucosaminidase*/metabolism ; Hyaluronoglucosaminidase*/Hyaluronoglucosaminidase*/Hyaluronoglucosaminidase*/genetics ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives

  • Source: Biomolecules [Biomolecules] 2024 Nov 17; Vol. 14 (11). Date of Electronic Publication: 2024 Nov 17.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101596414 Publication Model: Electronic Cited Medium: Internet ISSN: 2218-273X

Record details

Read More Add to Saved list
×
Academic Journal

Stromal Reprogramming Optimizes KRAS-Specific Chemotherapy Inducing Antitumor Immunity in Pancreatic Cancer.

  • Authors : Hu Q; College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310032, China.; Feng J

Subjects: Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/drug therapy ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/pathology ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/immunology

  • Source: ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2024 Nov 13; Vol. 16 (45), pp. 61583-61598. Date of Electronic Publication: 2024 Oct 31.Publisher: American Chemical Society Country of Publication: United States NLM ID: 101504991 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma.

  • Authors : Li Z; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China.; Fan X

Subjects: Albumins*/Albumins*/Albumins*/administration & dosage ; Albumins*/Albumins*/Albumins*/therapeutic use ; Albumins*/Albumins*/Albumins*/pharmacology gemcitabine-oxaliplatin regimen

  • Source: The oncologist [Oncologist] 2024 Nov 04; Vol. 29 (11), pp. 997-e1614.Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Flurbiprofen inhibits cAMP transport by MRP4/ABCC4 increasing the potency of gemcitabine treatment in PDAC cell models.

  • Authors : Cerviño RH; Instituto de Investigaciones Farmacológicas (Universidad de Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas), Facultad de Farmacia y Bioquímica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.; Gómez N

Subjects: Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/pharmacology ; Multidrug Resistance-Associated Proteins*/Multidrug Resistance-Associated Proteins*/Multidrug Resistance-Associated Proteins*/metabolism

  • Source: International journal of biological macromolecules [Int J Biol Macromol] 2024 Nov; Vol. 280 (Pt 4), pp. 136386. Date of Electronic Publication: 2024 Oct 06.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7909578 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

The interaction between UBR7 and PRMT5 drives PDAC resistance to gemcitabine by regulating glycolysis and immune microenvironment.

  • Authors : Feng M; Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.; Jiao Q

Subjects: Carcinoma, Pancreatic Ductal*/Carcinoma, Pancreatic Ductal*/Carcinoma, Pancreatic Ductal*/drug therapy ; Carcinoma, Pancreatic Ductal*/Carcinoma, Pancreatic Ductal*/Carcinoma, Pancreatic Ductal*/genetics ; Carcinoma, Pancreatic Ductal*/Carcinoma, Pancreatic Ductal*/Carcinoma, Pancreatic Ductal*/pathology

  • Source: Cell death & disease [Cell Death Dis] 2024 Oct 18; Vol. 15 (10), pp. 758. Date of Electronic Publication: 2024 Oct 18.Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA/PPA2c/mTORC1 axis.

  • Authors : Li G; Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Fujian Medical University Cancer Center, Fuzhou, China.

Subjects: Gemcitabine* ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/pharmacology

  • Source: Cell death & disease [Cell Death Dis] 2024 Oct 11; Vol. 15 (10), pp. 742. Date of Electronic Publication: 2024 Oct 11.Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  845 results for ""Deoxycytidine""